Company intelligence / Profile preview

Perspectum

Oxford, England, United Kingdomperspectum.com ↗

Ownership: Private
Development stage: Commercial

Overview

Perspectum’s non-invasive MRI-based digital diagnostics have been validated in over 50 clinical trials for chronic liver disease and are commercially available. Their cT1 biomarker predicts clinical outcomes in chronic liver disease; their MRCP+ product has FDA clearance. The company continues to expand into multi-organ imaging and oncology applications with ongoing research collaborations and new grants from the FDA.

Therapeutic areas: GastroenterologyMetabolic DisordersOncologyInfectious Diseases
Modalities: DeviceSoftwareImaging biomarker
Industry: Medical Imaging

Partnerships

University of Oxford

Beyond the preview

Go deeper on Perspectum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perspectum.

Explore the full profile